BioCryst Pharmaceuticals
BCRX
103 hedge funds and large institutions have $248M invested in BioCryst Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 10 closing their positions.
68% more capital invested
Capital invested by funds: $147M → $248M (+$100M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 100 → 103 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
6% less call options, than puts
Call options by funds: $5.36M | Put options by funds: $5.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17.6M |
| 2 |
RI
RTW Investments
New York
|
+$7.86M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$5.51M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.86M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$16.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.22M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
-$1.17M |
| 4 |
Goldman Sachs
New York
|
-$996K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$727K |
BCRX Hedge Fund Activity: Q3 2016 in Review
103 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2016, worth a combined $248M — up 68% from $147M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BCRX positions and 10 closed out — a net gain of 3 holders — while 29 added to existing stakes and 29 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $17.6M. The largest seller was Baker Bros. Advisors, cutting an estimated $16.2M.
- 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2016, up from 100 in Q2 2016.
- Funds reported $248M of BioCryst Pharmaceuticals stock for Q3 2016, up 68% quarter-over-quarter.
- 13 funds opened new BioCryst Pharmaceuticals positions in Q3 2016 and 10 closed out, a net change of +3 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2016 was Deerfield Management, an estimated $17.6M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2016 was Baker Bros. Advisors, an estimated $16.2M sold.
Based on aggregated 13F filings for Q3 2016.